Raltegravir: a new choice in HIV and new chances for research.
Emery
Sean
S
Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia. semery@nchecr.unsw.edu.au
Winston
Alan
A
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use; D048588:Benzoxazines / Q000627:therapeutic use; D003521:Cyclopropanes; D017277:Drug Approval; D004341:Drug Evaluation; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008017:Life Expectancy; D018579:Patient Selection; D011379:Prognosis; D011760:Pyrrolidinones / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D000068898:Raltegravir Potassium
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; C098320:efavirenz